在接受PCI的患者中,与使用康格雷洛相关的时间,指示和过渡模式
Angelo Oliva1,2, Davide Cao1,2, Mark Shneyderman1
1The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY, 10029, USA.
微笑研究发现,高风险的皮肤冠状动脉干预 (PCI) 患者从康格洛尔转换为蒂卡格洛尔显著减少了重大心脏和脑血管不良事件 (MACCE). 坚持标准化过渡协议是获得更好的结果的关键.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 最佳的抗血小板治疗对于皮肤穿刺冠状动脉干预 (PCI) 后至关重要,以减轻血栓和出血风险.
- 康格洛尔是一种静脉注射的P2Y12抑制剂,对高风险的PCI患者至关重要,包括患有急性冠状动脉综合征 (ACS) 或无法服用口服药物的患者.
研究的目的:
- 评估在高风险PCI患者中使用康格罗尔的现实世界.
- 评估从香草转换为口服P2Y12抑制剂对临床结果的影响.
主要方法:
- 西奈山PCI注册表的回顾性分析 (2018年1月至2024年3月).
- 检查了493名高风险的PCI患者接受康格洛尔治疗,重点是过渡到蒂卡格洛尔,克洛皮多格雷尔或普拉苏格雷尔.
- 主要终点:住院主要不良心脏和脑血管事件 (MACCE).
主要成果:
- 78.7%的患者患有ACS,79.3%接受了复杂的PCI.
- 与烯二相比,过渡到提卡格勒 (80.5%) 与较低的MACCE (9.8%与24.0%) 相关.
- 遵守过渡协议与降低的MACCE相关 (10.9%对比19.4%).
结论:
- 标准化过渡方案,特别是对提卡格勒罗的过渡方案,改善了康格勒罗治疗高风险PCI患者的临床结果.
- 在危急病患者中,康格勒输液耐受性良好.
- 需要在不同的环境中进行进一步的验证.
更多相关视频
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
相关概念视频
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Angina IV: Management
Acute Coronary Syndrome IV: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Cardiac Catheterization I: Pre-Procedure Overview
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
